Factors | Number (%) | HR (95% CI) | P value |
---|---|---|---|
Age | |||
< 60 years | 162 (46.29) | Reference | |
≥ 60 years | 188 (53.71) | 0.98 (0.97, 1.00) | 0.0297 |
Sex | |||
Male | 254 (72.57) | Reference | |
Female | 96 (27.43) | 0.88 (0.62, 1.26) | 0.4927 |
KPS | |||
70–80 | 242 (69.14) | Reference | |
90–100 | 108 (30.86) | 1.00 (0.98, 1.03) | 0.7220 |
Primary Site | |||
Rectum | 266 (76.00) | Reference | |
Rectosigmoid | 84 (24.00) | 1.12(0.53,1.18) | 0.6210 |
T Stage | |||
T2 | 24 (6.86) | Reference | |
T3 | 176 (50.29) | 2.86 (1.05, 7.83) | 0.0406 |
T4 | 150 (42.86) | 3.16 (1.15, 8.64) | 0.0253 |
N Stage | |||
N0 | 50 (14.29) | Reference | |
N1 | 114 (32.57) | 0.88 (0.44, 1.75) | 0.7192 |
N2 | 86 (24.57) | 2.03 (1.05, 3.93) | 0.0350 |
N+ | 86 (24.57) | 4.09 (2.21, 7.59) | < 0.0001 |
Nx | 14 (4.00) | 7.01 (3.14, 15.66) | < 0.0001 |
M Stage | |||
M1a | 180 (51.43) | Reference | |
M1b | 146 (41.71) | 1.09 (0.77, 1.54) | 0.6163 |
M1c | 24 (6.86) | 2.39 (1.46, 3.91) | 0.0006 |
Differentiation | |||
Well | 28 (8.00) | Reference | |
Moderate | 198 (56.57) | 0.28 (0.17, 0.47) | < 0.0001 |
Poor | 110 (31.43) | 1.00 (0.61, 1.65) | 0.9877 |
Unknown | 14 (4.00) | 0.95 (0.22, 4.07) | 0.9444 |
Chemotherapy Cycles | |||
4–8 | 247(70.57) | Reference | |
9–12 | 103(29.43) | 0.79 (0.69, 0.90) | 0.0002 |
Second-line Chemotherapy | |||
No | 276 (78.86) | Reference | |
Yes | 74 (21.14) | 0.37 (0.22, 0.63) | 0.0002 |
Chemotherapy Response | |||
Poor | 146 (41.71) | Reference | |
Good | 204 (58.29) | 0.82 (0.59, 1.13) | 0.0217 |
Metastatic Tumor radiotherapy | |||
Yes | 180 (51.43) | Reference | |
No | 170 (48.57) | 1.53 (1.11, 2.11) | 0.0102 |
Primary Tumor Radiotherapy | |||
No | 187 (53.43) | Reference | |
Yes | 163 (46.57) | 0.39 (0.28, 0.56) | < 0.0001 |